Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H22FN7O3.H2O |
| Molecular Weight | 481.4796 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C5=CN(C)N=C5)C2=O)N=C1
InChI
InChIKey=FQOJZRILDACBLT-PFEQFJNWSA-N
InChI=1S/C23H22FN7O3.H2O/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16;/h4-5,8-14H,6-7H2,1-3H3;1H2/t14-;/m1./s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C23H22FN7O3 |
| Molecular Weight | 463.4643 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27196749 |
http://www.amgenoncology-international.com/#/our-products/our-pipeline/
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27196749 |
http://www.amgenoncology-international.com/#/our-products/our-pipeline/
AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the cell surface enzyme called c-Met, which, when dysregulated, stimulates cancer cell scattering, invasion and protection from apoptosis. AMG 337, currently in Phase 2 development for the treatment of gastric and esophageal adenocarcinoma. In addition, recently was shown, that AMG 337 a promising and novel therapeutic strategy for targeting hepatocellular carcinomas with a dependence on HGF/MET signaling.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.01 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30425090 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMG-337 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
47.8 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30425090 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMG-337 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30425090 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMG-337 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. | 2016-07 |
|
| Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity. | 2016-03-24 |
|
| Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. | 2015 |
Sample Use Guides
150 mg, 200 mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: It was determined the effects of AMG 337 on the proliferation of a limited panel of cell lines with varying MET copy numbers, and was revealed that high-level focal MET amplification (>12 copies) was required to confer MET oncogene addiction and AMG 337 sensitivity. One MET-amplified cell line, H1573 (>12 copies), was AMG 337 insensitive, possibly because of a downstream G12A KRAS mutation. Mechanism-of-action studies in sensitive MET-amplified cell lines demonstrated that AMG 337 inhibited MET and adaptor protein Gab-1 phosphorylation, subsequently blocking the downstream PI3K and MAPK pathways.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:58:52 GMT 2025
by
admin
on
Mon Mar 31 20:58:52 GMT 2025
|
| Record UNII |
H9QF5PWS0D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
H9QF5PWS0D
Created by
admin on Mon Mar 31 20:58:52 GMT 2025 , Edited by admin on Mon Mar 31 20:58:52 GMT 2025
|
PRIMARY | |||
|
1643590-78-6
Created by
admin on Mon Mar 31 20:58:52 GMT 2025 , Edited by admin on Mon Mar 31 20:58:52 GMT 2025
|
PRIMARY | |||
|
122201344
Created by
admin on Mon Mar 31 20:58:52 GMT 2025 , Edited by admin on Mon Mar 31 20:58:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
